These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19905893)

  • 1. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.
    Manuri PV; Wilson MH; Maiti SN; Mi T; Singh H; Olivares S; Dawson MJ; Huls H; Lee DA; Rao PH; Kaminski JM; Nakazawa Y; Gottschalk S; Kebriaei P; Shpall EJ; Champlin RE; Cooper LJ
    Hum Gene Ther; 2010 Apr; 21(4):427-37. PubMed ID: 19905893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
    PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.
    Jin Z; Maiti S; Huls H; Singh H; Olivares S; Mátés L; Izsvák Z; Ivics Z; Lee DA; Champlin RE; Cooper LJ
    Gene Ther; 2011 Sep; 18(9):849-56. PubMed ID: 21451576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.
    Tsukahara T; Iwase N; Kawakami K; Iwasaki M; Yamamoto C; Ohmine K; Uchibori R; Teruya T; Ido H; Saga Y; Urabe M; Mizukami H; Kume A; Nakamura M; Brentjens R; Ozawa K
    Gene Ther; 2015 Feb; 22(2):209-15. PubMed ID: 25427612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleeping beauty system to redirect T-cell specificity for human applications.
    Maiti SN; Huls H; Singh H; Dawson M; Figliola M; Olivares S; Rao P; Zhao YJ; Multani A; Yang G; Zhang L; Crossland D; Ang S; Torikai H; Rabinovich B; Lee DA; Kebriaei P; Hackett P; Champlin RE; Cooper LJ
    J Immunother; 2013 Feb; 36(2):112-23. PubMed ID: 23377665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.
    Choi Y; Yuen C; Maiti SN; Olivares S; Gibbons H; Huls H; Raphael R; Killian TC; Stark DJ; Lee DA; Torikai H; Monticello D; Kelly SS; Kebriaei P; Champlin RE; Biswal SL; Cooper LJ
    Biomed Microdevices; 2010 Oct; 12(5):855-63. PubMed ID: 20574820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.
    Huls MH; Figliola MJ; Dawson MJ; Olivares S; Kebriaei P; Shpall EJ; Champlin RE; Singh H; Cooper LJ
    J Vis Exp; 2013 Feb; (72):e50070. PubMed ID: 23407473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.
    Singh H; Manuri PR; Olivares S; Dara N; Dawson MJ; Huls H; Hackett PB; Kohn DB; Shpall EJ; Champlin RE; Cooper LJ
    Cancer Res; 2008 Apr; 68(8):2961-71. PubMed ID: 18413766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Nonviral
    Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
    Front Immunol; 2021; 12():802705. PubMed ID: 35082789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
    Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
    Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
    Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
    J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
    Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
    Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
    Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A transposon and transposase system for human application.
    Hackett PB; Largaespada DA; Cooper LJ
    Mol Ther; 2010 Apr; 18(4):674-83. PubMed ID: 20104209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.
    Chicaybam L; Abdo L; Bonamino MH
    Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
    Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
    Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of piggyBac-mediated anti-CD19 CAR-T cells after ex vivo expansion with aAPCs or magnetic beads.
    Yang LR; Li L; Meng MY; Wang WJ; Yang SL; Zhao YY; Wang RQ; Gao H; Tang WW; Yang Y; Yang LL; Liao LW; Hou ZL
    J Cell Mol Med; 2021 Jan; 25(2):686-700. PubMed ID: 33225580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.